NFKB1 and prostate cancer: The NFKB1 -94 polymorphism was shown to decrease prostate cancer risk in both heterozygous and homozygous comparison models (odds ratios of 0.74 (95% CI = 0.58–0.96) (P = 0.02) and 0.57 (95% CI = 0.42–0.78) (P < 0.01), resp).